What's Happening?
Stimvia, a Czech medtech company, has completed a clinical study on its URIS device, which aims to treat symptoms of Parkinson's disease. The study, published in Clinical Parkinsonism & Related Disorders, involved 12 patients using the device for daily 30-minute sessions over six weeks. The URIS device employs peroneal electrical transcutaneous neuromodulation to alleviate motor symptoms such as resting tremor and improve patients' quality of life. The study reported no severe side effects, and 80% of participants chose to continue using the therapy after the initial phase. Stimvia plans to launch a two-year follow-up study and is preparing for a larger international clinical trial to further validate these findings.
AD
Why It's Important?
Parkinson's disease affects over 10 million people worldwide, causing significant motor dysfunction and impacting daily life. The URIS device offers a non-invasive alternative to deep brain stimulation, potentially slowing disease progression and improving quality of life. This development is significant for patients seeking less invasive treatment options and could influence future Parkinson's therapies. The study's positive results may encourage further investment and research into neuromodulation technologies, potentially benefiting the healthcare industry and patients globally.
What's Next?
Stimvia is preparing for a larger international clinical trial to confirm the promising results of the URIS device. This trial will involve experts from several European countries and aims to validate the device's efficacy on a broader scale. The company is also launching a two-year follow-up study for participants who have experienced tangible health benefits, which could provide further insights into the long-term effects of the therapy.
